Rating Change
HC Wainwright & Co. reiterated its Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on November 17, 2026.
HC Wainwright & Co. reiterated its Buy rating on Alnylam Pharmaceuticals, Inc.

At publication ·
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) · reiterate
At a glance
HC Wainwright & Co. reiterated its Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on November 17, 2026.
Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $157.79 with a market capitalization of $44.2B. The stock has declined 64.8% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Alnylam Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 17, 2026 | HC Wainwright & Co. | Buy | N/A |
| Nov 17, 2026 | Cantor Fitzgerald | Neutral | N/A |
| Nov 02, 2026 | Barclays | Overweight | N/A |
| Nov 02, 2026 | Truist Securities | Hold | N/A |
| Nov 02, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ALNY Stock Page
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ALNY forecast page.
Current market data
NASDAQ · ALNY
$147.82
Down: -$1.58 · -1.06%
Live quote updated
Keep reading
analyst ·
institutional ·
price ·
price ·